GVR Report cover Genitourinary Drugs Market By Indication (Prostate, Ovarian, Bladder, Cervical Cancer, Erectile Dysfunction, UTI, Urinary Incontinence & STD) By Product (Urologicals, Hormonal Therapy Drugs, Gynecological, Anti-infectives) And Segment Forecasts, 2018 - 2024Report

Genitourinary Drugs Market By Indication (Prostate, Ovarian, Bladder, Cervical Cancer, Erectile Dysfunction, UTI, Urinary Incontinence & STD) By Product (Urologicals, Hormonal Therapy Drugs, Gynecological, Anti-infectives) And Segment Forecasts, 2018 - 2024

  • Report ID: GVR-1-68038-285-3
  • Number of Pages: 110
  • Format: Electronic (PDF)
  • Historical Range: 2013 - 2015
  • Industry: Healthcare

Industry Insights

The global genitourinary drugs market accounted for USD 28.2 billion in 2015 and is anticipated to grow at a CAGR of over 0.8% during the forecast period. The growing prevalence of genitourinary disorders is presumed to be the high rendering impact driver of this vertical. In addition, increasing number of pipeline drugs are expected to widen the scope for growth in the future.

However, in the present scenario, the influx of a wide range of counterfeit and generics launched by big pharmaceutical companies as well as small and medium-sized drug manufacturers is expected to slow down the market growth. Furthermore, continual patent expirations throughout the forecast period are presumed to inhibit the growth of this sector to a considerable level.

Genitourinary drugs market, by product, 2013 - 2024 (USD Million)

Genitourinary drugs market

The vast array of pipeline drugs with a high probability of clearing clinical trials in the future is anticipated to serve as a significant growth driver. For instance, currently, 47 and 16 medications for cervical cancer are in clinical development phase and phase-II stages respectively, which exemplify the rapidly growing research platform.

The aforementioned factor is believed to be a consequence of collaborative research initiatives conducted by the major pharmaceutical companies consistently striving to strengthen their leadership position in the branded genitourinary drugs market space. For instance, in September 2016, Bristol-Myers Squibb announced its collaboration with Nektar Therapeutics to evaluate the combined efficacy of NKTR-214 and Opdivo (nivolumab) in treating five tumor types, including bladder cancer.

Indication Insights

The prostate cancer segment held the largest share of over 25.0% in the indication segment in 2015. The aforementioned can be attributed to a wide range of therapeutics, such as immunotherapy medication, radiopharmaceuticals, and anti-neoplastic agents, available to treat prostate cancer. Associated benefits, such as heightened survival chances, impeded disease progression, and limited adverse effects, are steadily increasing their uptake in the market.

Moreover, in the future, with advancements in formulation techniques, next generation therapeutics is anticipated to eliminate the need for invasive surgeries. For instance, the launch of Xofigo (Radium-223) to treat advanced prostate cancer patients who have developed resistance to traditional chemotherapeutic and hormone therapy agents.

Product Insights

The presence of an extensive drug pipeline furnishing a wider product range for reproductive disorders in women is responsible for the emergence of the gynecological products segment. The high need for therapeutics in this space is expected to create profitable opportunities for segment growth in the future.

Genitourinary drugs indication market, 2015 & 2024 (USD Million)

Genitourinary drugs indication market

In addition, high focus of government healthcare organizations on the enhancement of reproductive health of women is anticipated to provide lucrative growth prospects.

Regional Insights

In 2015, North America held a large share of over 42.0% of the global market space. The majority share can be attributed to the high prevalence of major genitourinary diseases in this region. For instance, prostate cancer that constitutes the larger share of all genitourinary cancer types is the second-most leading cause for all cancer-related deaths, which serves as a significant factor, contributing toward the surging demand for the therapeutics in this region.

U.S. genitourinary drugs market share, by product, 2015

U.S. genitourinary drugs market

On the other hand, Asia Pacific genitourinary drugs vertical is expected to grow at a lucrative rate during the forecast period. The sector is driven by high R&D investment deployed by the global players and their consistent efforts to commercialize branded therapeutics at a relatively low price.

In addition, the urgent need to curb the high incidence rate of target disorders, rising disposable income that raises the probability of usage of branded drugs, and continual improvements in healthcare infrastructure are presumed to present the vertical with significant growth opportunities over the forecast period. Furthermore, growth is due to the high R&D intensity and the growing awareness in the emerging economies, such as China and India.

Competitive Insights

The registered growth in this sector is a consequence of the implementation of rigorous strategies including new product development & geographical expansion initiatives and mergers & acquisitions. In May 2016, Novartis AG divided its pharmaceutical division into Novartis pharmaceuticals and Novartis oncology. This was carried out to increase focus and improve operational execution to enhance the growth prospects of the company.

In addition, in May 2016, Genentech, Inc. received FDA approval for Tecentriq to treat patients suffering from a specific type of bladder cancer, urothelial carcinoma; thus addressing the unmet needs of the patient base. This sector is currently fragmented in nature owing to the increasing presence of several major companies and new entrants.

Genitourinary Drugs Report Scope



Base year for estimation


Actual estimates/Historic data

2013 - 2015

Forecast period

2016 - 2024

Market representation

Revenue in USD Million & CAGR from 2016 to 2024

Regional scope

North America, Europe, Asia Pacific, Latin America, and MEA

Country scope

U.S., Canada, UK, Germany, Japan, China, Brazil, Mexico, South Africa

Report coverage             

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth and provides an analysis on the industry trends in each of the sub-segments from 2013 to 2024. For the purpose of this study, Grand View Research has segmented the genitourinary drugs market on the basis of product, application, end-use, and region:

  • Indication Outlook (Revenue, USD Million, 2013 – 2024)
    • Prostate Cancer
    • Ovarian Cancer
    • Bladder Cancer
    • Cervical Cancer
    • Renal Cancer
    • Erectile Dysfunction
    • Urinary Tract Infections
    • Urinary Incontinence & Overactive Bladder
    • Sexually Transmitted Diseases
    • Interstitial Cystitis
    • Hematuria
    • Benign Prostatic Hyperplasia
  • Product Outlook (Revenue, USD Million, 2013 - 2024)
    • Urologicals
    • Hormonal Therapy
    • Gynecological
    • Anti-infectives
    • Others
  • Regional Outlook (Revenue, USD Million, 2013 - 2024)
    • North America
      • U.S
      • Canada
    • Europe
      • Germany
      • UK
    • Asia Pacific
      • Japan
      • China
      • India
    • Latin America
      • Mexico
    • Middle East and Africa
      • South Africa
gvr icn


gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon